Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS

About this episode

The episode introduces Joint Ventures, a podcast focused on advances in rheumatologic disease and their implications for clinical practice.

Introducing Joint Ventures — a new podcast exploring advances in rheumatologic disease and what they mean for real-world practice. Hosted by RheumatologyLive, the series is led by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 United Kingdom-based rheumatologists united by a shared interest in translating rapidly evolving science into thoughtful, patient-centered care. Joint Ventures is designed for rheumatologists and clinicians managing immune-mediated disease who are navigating an increasingly complex therapeutic landscape. Each episode will examine emerging evidence, new mechanisms of action, and shifting paradigms in rheumatology, with a focus on how these developments intersect with clinical reasoning, uncertainty, and long-term patient management. Arnold is an academic clinical lecturer in rheumatology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine in University of Leeds, with research interests spanning systemic lupus erythematosus, clinical trials, and the application of deep learning in medicine. Buss is a consultant rheumatologist specializing in psoriatic arthritis at Newcastle’s Freeman Hospital, with a particular focus on integrating new data…

People in this episode

Hosts: Jack Arnold, MBBS, PhD, Rihards Buss, MBBS

Topics covered

• rheumatologic disease
• patient-centered care
• immune-mediated disease
• therapeutic landscape
• clinical reasoning
• long-term patient management

Keywords

• rheumatology
• clinical trials
• deep learning
• emerging evidence
• mechanisms of action
• therapeutic landscape

Mentioned in this episode

Organizations: RheumatologyLive, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Newcastle’s Freeman Hospital

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min